ASH 2024: Updates in the Treatment of CLL - Episode 13

Real-World Observations With Pirtobrutinib and New Data From the BRUIN CLL-321 Trial at ASH 2024

Panelists discuss how real-world experience with pirtobrutinib generally aligns with the BRUIN study’s progression-free survival (PFS) data while sharing insights about common reasons for discontinuation and interpreting updated BRUIN CLL-321 trial results from ASH 2024 that may influence clinical decision-making regarding pirtobrutinib use in practice.

EP. 1: Expert Insights in Selecting Frontline Therapies in TN CLL: Fixed-Duration Venetoclax vs Continuous BTKi
EP. 2: ASH 2024 Updates: SEQUOIA 5-Year Follow-Up and Expert Perspectives in Selecting Between Acalabrutinib vs Zanubrutinib in TN CLL
EP. 3: Real-World Observations: Firstline cBTKi Switches and Cardiac AEs in TN CLL
EP. 4: Clinical Insights: Exploring Combination Regimens in First-Line Treatment in CLL: SEQUOIA Arm D and BOVen Trials
EP. 5: Key Takeaways From the AMPLIFY Trial at ASH 2024: Fixed-Duration Acalabrutinib Plus Venetoclax With or Without Obinutuzumab vs Chemoimmunotherapy in TN CLL
EP. 6: ASH 2024 Updates: Evaluating Potential Frontline Triplet Regimen: Pirtobrutinib Plus Venetoclax Plus Obinutuzumab in TN CLL
EP. 7: Expert Perspectives: Navigating the Emerging Treatment Landscape of Combination Therapies in TN CLL—Applying Evidence to Clinical Practice
EP. 8: Expert Insights: Treatment Selection in Second-Line R/R CLL and Limitations of Applying MAIC Data in the Real-World Practice Setting
EP. 9: ASH 2024 Highlights: Phase 2 Study of Zanubrutinib Plus Venetoclax in R/R CLL
EP. 10: Treatment Sequencing in R/R CLL: Optimizing Strategies and Clinical Insights From ASH 2024 Real-World Data
EP. 11: Pirtobrutinib in R/R CLL: Can It Be Used in the Second-Line Setting?
EP. 12: Sequencing Treatment in R/R CLL: CAR T-Cell Therapy vs Pirtobrutinib in Double-Exposed Patients
Now Viewing
EP. 13: Real-World Observations With Pirtobrutinib and New Data From the BRUIN CLL-321 Trial at ASH 2024
EP. 14: Emerging Data on BTK Inhibitor Degraders and Bispecifics in R/R CLL: Updated Results at ASH 2024

Video content above is prompted by the following:

  • Have you observed similar median PFS duration with pirtobrutinib as reported out in the BRUIN study? What are your top clinical observations for patients having to discontinue or switch off pirtobrutinib?
  • The BRUIN CLL-321 trial had data updates at ASH; could you sharekey highlights and your impressions so far and whether you anticipate this data to influence your use of pirtobrutinib in the real-life clinical setting?